Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,536 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,903 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05610852 | Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound | recruiting | N/A | 276 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06145633 | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 15 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06907446 |
| Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies |
| recruiting |
| N/A |
| 50 |
| University of California, DavisOTHER |
| 1 |
| Aug 6, 2026 |
| clinicaltrials |
| NCT07144228 | Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer | recruiting | — | 300 | Duke UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07223385 | High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe) | recruiting | Phase 2 | 80 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07455903 | Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT | recruiting | Phase 2 | 50 | Baptist Health South FloridaOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04030338 | Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer | active not recruiting | — | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07747272 | Nerve-SPARing Robotic Prostatectomy: The Impact of Patient Baseline Profiles on Erectile Function(SPARE-EF) | recruiting | — | 300 | University of FlorenceOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07747493 | 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy(PSMA-FT) | not yet recruiting | N/A | 8 | University Health Network, TorontoOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03531099 | Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer(HIFUSA) | active not recruiting | Phase 3 | 108 | Hospices Civils de LyonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05995236 | Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy | terminated | — | 35 | Methodist Health SystemOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06687538 | Effect of Education to be Provided to Patients to Undergo TURP With Mobile Application on Patient Outcomes | completed | N/A | 68 | Tarsus UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07364071 | Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer(SENTRY) | recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07650448 | WATER IV PCa (AS Sub-study) | not yet recruiting | N/A | 333 | PROCEPT BioRoboticsINDUSTRY | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | terminated | Phase 2 | 46 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy | suspended | N/A | 100 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07225309 | A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer | recruiting | N/A | 300 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07433140 | Effect of Rectus Block Timing on Opioid Use(PROSTIMERSBOP) | completed | N/A | 50 | Koc University HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741929 | Patient and Provider Perspectives on Genetic Risk Profiling(PPP) | recruiting | — | 40 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT00967863 | Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18) | active not recruiting | N/A | 500 | UNICANCEROTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02893917 | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03269422 | Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL) | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03517969 | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT05828082 | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06613100 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | recruiting | Phase 1 | 40 | AmgenINDUSTRY | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06625970 | Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse(PEACE 7) | recruiting | Phase 3 | 700 | UNICANCEROTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06954337 | MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial | recruiting | N/A | 1,750 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739121 | Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations(BEACON) | recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07740239 | A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial(COSMOS-I) | recruiting | — | 2,050 | Tampere University HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03606837 | 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging(PROSTATEP) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04108208 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) | completed | Phase 4 | 75 | Janssen Research & Development, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04879940 | Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization | active not recruiting | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05751434 | A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer | recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05754658 | African Cancer Genome: GMD | completed | — | 854 | Fox Chase Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06325046 | Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer | recruiting | N/A | 164 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06604130 | Plasma Exosome RNA to Diagnose Prostate Cancer(exo-PRECISE) | enrolling by invitation | N/A | 1,600 | Xijing HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07203482 | Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation | recruiting | — | 300 | NYU Langone HealthOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 205 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07737457 | MICRO-ultrasound Guided Prostate SBRT(MICRO-S) | not yet recruiting | N/A | 112 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01542021 | Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer | completed | N/A | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | terminated | Phase 3 | 166 | Canadian Urologic Oncology GroupOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03246347 | A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05327465 | Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy | recruiting | N/A | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 6, 2026source: clinicaltrials